{"name":"Nanjing Leads Biolabs Co.,Ltd","slug":"nanjing-leads-biolabs-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Axitinib Tablets","genericName":"Axitinib Tablets","slug":"axitinib-tablets","indication":"Advanced renal cell carcinoma","status":"phase_1"},{"name":"Tislelizumab Injection","genericName":"Tislelizumab Injection","slug":"tislelizumab-injection","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"LBL-024 for Injection","genericName":"LBL-024 for Injection","slug":"lbl-024-for-injection","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Axitinib Tablets","genericName":"Axitinib Tablets","slug":"axitinib-tablets","phase":"phase_1","mechanism":"Axitinib is a selective inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3).","indications":["Advanced renal cell carcinoma"],"catalyst":""},{"name":"LBL-024 for Injection","genericName":"LBL-024 for Injection","slug":"lbl-024-for-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tislelizumab Injection","genericName":"Tislelizumab Injection","slug":"tislelizumab-injection","phase":"phase_3","mechanism":"Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of immune cells, to inhibit the immune system's attack on cancer cells.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic esophageal squamous cell carcinoma","Locally advanced or metastatic urothelial carcinoma","Adenocarcinoma of the stomach","Gastric cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiT0FVX3lxTE9kd1dnblhKakVTYXBYRG5yRUxvZ2NsUHk0N09WMkNyVXIweURkYzdYOExHYkN1NjNHa3c0WDdReDFBRjh3TDdud1RjS1ZTZjA?oc=5","date":"2026-04-07","type":"pipeline","source":"Meyka","summary":"Nanjing Leads Biolabs Co Ltd (9887.HK) Competitors - Meyka","headline":"Nanjing Leads Biolabs Co Ltd (9887.HK) Competitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxPdW9zRzNXNWh1VHhUUm9RaktCZG94QjlkMUtKUEpicXM0eW9HeUJtellzdVBWbXl5N3V2U1FGTlY3bWh1V3pWOGU4TzdnaEt4UG5qX09wM2t5YTJCTi11clB4Q2FlUmszTGxIamJtSEF3MDktcG9obXZIdXFjdEJnX1E3aVUxUzNUNzRQSFVvZXI4VTlTUmc3NUYxeS1YNnNXdFk2N242WmdCcDNVY2J0TDBUTEZxSzJ3NUd0dHBBWVgxSmxkT1VpbHd2OTlGXzBhM0dSZmV6ak9pMmp5Q0NCMWlFUmZhZlZVclNOMUZRM0fSAfYBQVVfeXFMTzViLTZKRXJYTi1IUGNJelhvdzhtYzRxOXNGOEJVZlMwNDNCa195REVPSWFVRURhU0ViVUxuVEdHODl4S25jZUtPeWt2SGt4Y182QkQ4dDlyVG1OdFZrcmVFSUItZGctaWMwUm1RS1lBRV9HdHREdE51bFNUVlhkanFDYlI1REVDLXBpU2RMR21HMWozRTVsV1NqMVplMzVXRl85UjlGeFVJX183bmNyWHpQd05QaHUtUG5KSVlSVENoY1VaQzFtbWJoUDJLRXlFbGswLUhyNFQyN2p2emFacUlJY2UyZUFia3lQajJqemxmd21FNEhn?oc=5","date":"2026-04-01","type":"earnings","source":"simplywall.st","summary":"Asian Growth Stocks Insiders Favor With Up To 58% Revenue Growth - simplywall.st","headline":"Asian Growth Stocks Insiders Favor With Up To 58% Revenue Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxOaFQ3OGR5UnZUbVZRV015bExQazl3MkxMYi0yekplYk9TVVMxNlM5Ul9hd0NOQ3RLUGdwcjgwYzZzSWZ5SFZocnJJQ3N4LUY3OWhYQVpsZ3E2SndlaFA2S1BfX2hrSkFsaVBGZ1hJU2RDNTZ4ekF6clE3Qm9Ia3RtQlhCVzRuYjMwUEFtZldVcmhoWFlsdkNmeDZhUldhTFVsdXJkY3l0UGxhMGpwS1VzVzFXNWpZLWNUcHJCZlNaN01PVkVPRnBfU2gxTUVEWXlEU0VVQ2FMdlk5MUM0TUFycDFndw?oc=5","date":"2026-03-17","type":"regulatory","source":"TipRanks","summary":"Nanjing Leads Biolabs Sets March 2026 Board Meeting to Approve 2025 Results and Consider Dividend - TipRanks","headline":"Nanjing Leads Biolabs Sets March 2026 Board Meeting to Approve 2025 Results and Consider Dividend","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxNNERoWG9zRzF4blQ2ZzE2SG5Qcmd5NVI3TE9NYllVczhYMEw0a2lKWGtNcW00Y1kxYWRSRkozRVN2ZFV1R3lvNm1wVmh2cS1tR1NOUXBGZWZVaTZEOHRfM2pPOG9TZjY4bjhpWEU5WkxBRGtUcGdKOUxzWkpXWHpPZTE4d09Ya1NVLTlNclZtOF9TcXVYUDdiUFNlV0otVFcwTGxWdF9UaWZwZzdjNlFmWFZOY2g0d3VZc0pjSWlVMWd0THVlUDlQdjc4dmhLMFlhTkZBbnh3eXlha3NFSnh6bWQ0RTZpWHA1OXl1elNQX2xhcDFNajMwbTBmRUxCdl9VM0plWXBTem8?oc=5","date":"2025-10-16","type":"pipeline","source":"Quiver Quantitative","summary":"Dianthus Therapeutics Initiates Licensing Agreement for DNTH212, a Promising Treatment for Autoimmune Diseases with Unique Mechanism of Action | DNTH Stock News - Quiver Quantitative","headline":"Dianthus Therapeutics Initiates Licensing Agreement for DNTH212, a Promising Treatment for Autoimmune Diseases with Uniq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOeFFKSmx6MFAwMVBBNUlfeElFWTVsVW5xTVlBZkVzMTdGUzlQbHlhYl9MMllJOV9KbTZxSU1Rbmc5LVJhYWR4aGFBODJySU9Wb2F6SUFySkdIUi1mZU9mdFFJUUY3NlJRTmdxYmtpaV9Zd3doVjlXY2NucHhyNnNaVzdBenFVeEg2aU5hUE8zZWFjNGN3Qzl5NkNkckRHbWtfV2EwZWs3a0lhN2w5WXdKc0VkUDJBdXZNR0FRek9CNDFRUkxFQ2F6RnVGTThhU3VKLXc?oc=5","date":"2025-09-15","type":"trial","source":"BioPharma APAC","summary":"Leads Biolabs Doses First Patient in Phase 1b/II Trial of Opamtistomig for Advanced Melanoma - BioPharma APAC","headline":"Leads Biolabs Doses First Patient in Phase 1b/II Trial of Opamtistomig for Advanced Melanoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQejVOQWEzZlFvQV9sYlB3ZkpsbC1MdVk2aDBLa2gxOVF2S3RiT0dHUURIOWc3VVUzWGgyNHVOUVFfVW5WYmdiNlYtdVp0M2k3M25Rb2JldERDQTZnVGhiSUZveDlGOGRRdVB4cHhIRWNwXzRtU0YyeHlZWW5YeHB3WjBwWVhBY1pWT09oek1heGhzNnVuMHVibGl6Vy03YUk?oc=5","date":"2025-09-09","type":"pipeline","source":"BioWorld News","summary":"Biopharma IPO activity slows, but 2025 returns are surging - BioWorld News","headline":"Biopharma IPO activity slows, but 2025 returns are surging","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOZVMyX0xpd1hWQVdLZGpiS2g3aG1fQ3BEaGFnWWNmQ3h1cVVoRWpRbERNUGlpVlFTME5BNTFHWnVpV2E3Z2ZpYUdPb1QxMWc4aXM2bUdsUEM1RjZPcTJ3VUNBUHZ3MFliSndhbGItVm5Oa0ZIc29jY2JWMEgtMjczWVE1c2RKWWJsTWdGYjB1VzM0UUJ1SkhXN1JiZXVWTDF6Q0VfRnVPQnIxTXhVS29DWHhpYlhKUm0w?oc=5","date":"2025-07-25","type":"pipeline","source":"Fierce Biotech","summary":"Chinese antibody developer Leads Biolabs hits Hong Kong stock exchange in $189M IPO - Fierce Biotech","headline":"Chinese antibody developer Leads Biolabs hits Hong Kong stock exchange in $189M IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9wVEVWOEFSaXpIWmJGTXJaREVfYWw3X055bFYzYk52azZ5S0o4Tlh2V3pYRjJOQWdMR05uMjR4b2FGU0liakFXWjZIYVZrQlF2N0FtRGd3?oc=5","date":"2025-07-24","type":"pipeline","source":"sg.finance.yahoo.com","summary":"Nanjing Leads Biolabs Co., Ltd. (9887.HK) stock price, news, quote and history - sg.finance.yahoo.com","headline":"Nanjing Leads Biolabs Co., Ltd. (9887.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQRmdITkIzU1l0cTZ1VjZreGFMS19VLUxPOFdLLW9xeWdxMkIzaEg3VnJJSEk3SzBsSFNibUxSWTlpM1ZRcWthNllUT1d0OVBnd1lUUG85RkdUOWlrQWJIMHNyVElvVi1MUlNmczJNNUpZSV9QSlNQS3BCREVhYS1LS01nRUhESk9Ic0lLOGdkOHN2QjRHZlRESVdnbTdjbHdlTURz?oc=5","date":"2025-07-24","type":"pipeline","source":"BioWorld News","summary":"34 mainland China biotechs file for Hong Kong IPO in H1 2025 - BioWorld News","headline":"34 mainland China biotechs file for Hong Kong IPO in H1 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPdnNLbk5qQ0JGN2JoSUV4bERhMGlVX0k3cUNiRUVYdW1MMmJ3bHlINlBWbjE5Z3N5U1YtZm1LYzM0V19JZklSLUotV3pmdXpnb1hWNTEyY1Z1NHVyVFBUZnpXN3llSTc1TGt2cFRBLWhRcDRFa0lTU1ZhRWRCem5nc2hTcmc?oc=5","date":"2025-07-24","type":"pipeline","source":"Yahoo Finance","summary":"Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering - Yahoo Finance","headline":"Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxPQkUxRUsyYmFyUXRlNUR1cE85NGptaGxFWHlHd0RXdnVjSURjVlF6RmFhaTNUVHczd3Z0cXRJdXFnaUFXNTMtWVJ4dkl4Q1JRTFZFWVZHbFF6aHBiYjVtR2VWTlByTzY3bk9ZTmp1anRzTFJ2V1huUGVqYTRTXzlLVWFOcTRMX0xMT21TdXQ4YVRUcHliczg4TmxCOEtqaFgwQ3E3cUZWVE5weTV0OE40Zk9VTTlBMjRRUk5QZTN4V0xmeTZqSWdoVjAxSVdwQU56QnBGdHllc0Y3Mmo5X2J2a1BHWmlJVkRabUVxb1pHRlVnUmhFX1prZkhPTWQyaWpfaDhZNVVYb0pvMVNhVkRfWEtFeTBPdms?oc=5","date":"2024-11-07","type":"pipeline","source":"PR Newswire","summary":"Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders - PR Newswire","headline":"Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNX3pFcGFQWmpqaFhTdkEyLXY4T20tZ2JZZWNjSlc2Yl8yZjJIeWFqenJaUEJUbG5vRVU4OEN6MzNIQmpKWm5OdVpvLUd6N29HWnM1dVlqa3ZtRjAzekh2U19FaHFkUFdhOEctUkRlNjRBbmpwX3JEWXg0N2VLem1aWkxTay00NGctYXp3Yi1TRHdCclNYY1dTZXRhQWJ6RTkxcU1SR0JxMm9Jcm9fSUg3el9hQmtwTWFKeG94MzRlUmVQTGJCQ09JMWt4S0RwWEhsUUpQYQ?oc=5","date":"2024-11-07","type":"pipeline","source":"BioPharm International","summary":"Aditum Bio and Leads Biolabs Form New Company, Oblenio Bio, for Developing a Therapeutic Antibody to Treat Autoimmune Disorders - BioPharm International","headline":"Aditum Bio and Leads Biolabs Form New Company, Oblenio Bio, for Developing a Therapeutic Antibody to Treat Autoimmune Di","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":1,"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}